CT-996

CT-996 is an orally active GLP-1RA agonist, with an EC50 of 0.49 nM. CT-996 reduces the β-arrestin recruitment and GLP-1R internalization. CT-996 suppresses postprandial blood glucose following a mixed meal tolerance test (MMTT) in mice expressing the human GLP-1 receptor and enhances glucose stimulated insulin secretion (GSIS) during an intravenous glucose challenge in obese monkeys. CT-996 can be used for the study of type 2 diabetes (T2D) and obesity[1][2].

Product Specifications

CAS Number

[2810808-95-6]

Product Name Alternative

RO7795081; RG6652

UNSPSC

12352100

Target

Arrestin; GLP Receptor

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Purity

99.97

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C[C@@H](C[C@H](CC1)OC2=NC(COC3=C(C=C(C=C3)F)F)=NC=C2)N1CC(N(C4=C5)C[C@@H]6CCO6)=NC4=CC=C5C(O)=O

Molecular Formula

C30H31F2N5O5

Molecular Weight

579.59

References & Citations

[1]Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Aug;24 (8) :631-650. |[2]JIAN LUO, et al. Efficacy of CT-996, an Oral Small Molecule GLP-1 Receptor Agonist, in Human GLP-1 Receptor Knockin Mice and Obese Cynomolgus Monkeys. Diabetes 14 June 2024; 73 (Supplement_1) : 771–P.